Business Wire

VeriSilicon’s Scalable High-Performance GPGPU-AI Computing IPs Empower Automotive and Edge Server AI Solutions

Share

Provide AI acceleration with high computing density, multi-chip scaling, and 3D-stacked memory integration

VeriSilicon (688521.SH) today announced the latest advancements in its high-performance and scalable GPGPU-AI computing IPs, which are now empowering next-generation automotive electronics and edge server applications. Combining programmable parallel computing with a dedicated Artificial Intelligence (AI) accelerator, these IPs offer exceptional computing density for demanding AI workloads such as Large Language Model (LLM) inference, multimodal perception, and real-time decision-making in thermally and power-constrained environments.

VeriSilicon’s GPGPU-AI computing IPs are based on a high-performance General Purpose Graphics Processing Unit (GPGPU) architecture with an integrated dedicated AI accelerator, delivering outstanding computing capabilities to AI applications. The programmable AI accelerator and sparsity-aware computing engine accelerate transformer-based and matrix-intensive models through advanced scheduling techniques. These IPs also support a broad range of data formats for mixed-precision computing, including INT4/8, FP4/8, BF16, FP16/32/64, and TF32, and are designed with high-bandwidth interfaces of 3D-stacked memory, LPDDR5X, HBM, as well as PCIe Gen5/Gen6 and CXL. They are also capable of multi-chip and multi-card scale-out expansion, offering system-level scalability for large-scale AI application deployments.

VeriSilicon’s GPGPU-AI computing IPs provide native support for popular AI frameworks for both training and inference, such as PyTorch, TensorFlow, ONNX, and TVM. These IPs also support General Purpose Computing Language (GPCL) which is compatible with mainstream GPGPU programming languages, and widely used compilers. These capabilities are well aligned with the computing and scalability requirements of today’s leading LLMs, including models such as DeepSeek.

“The demand for AI computing on edge servers, both for inference and incremental training, is growing exponentially. This surge requires not only high efficiency but also strong programmability. VeriSilicon’s GPGPU-AI computing processors are architected to tightly integrate GPGPU computing with AI accelerator at fine-grained levels. The advantages of this architecture have already been validated in multiple high-performance AI computing systems,” said Weijin Dai, Chief Strategy Officer, Executive Vice President, and General Manager of the IP Division at VeriSilicon. “The recent breakthroughs from DeepSeek further amplify the need for maximized AI computing efficiency to address increasingly demanding workloads. Our latest GPGPU-AI computing IPs have been enhanced to efficiently support Mixture-of-Experts (MoE) models and optimize inter-core communication. Through close collaboration with multiple leading AI computing customers, we have extended our architecture to fully leverage the abundant bandwidth offered by 3D-stacked memory technologies. VeriSilicon continues to work hand-in-hand with ecosystem partners to drive real-world mass adoption of these advanced capabilities.”

About VeriSilicon

VeriSilicon is committed to providing customers with platform-based, all-around, one-stop custom silicon services and semiconductor IP licensing services leveraging its in-house semiconductor IP. For more information, please visit: www.verisilicon.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250608814759/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood Disorders9.6.2025 14:40:00 CEST | Press release

PYRUKYND® (mitapivat) is a first-in-class pyruvate kinase (PK) activator, approved by the European Commission for adults with PK deficiency The agreement includes commercialization and distribution rights for potential future indications Furthered by this partnership with Agios, Avanzanite is setting a new paradigm in biotech commercial and distribution partnerships, and in how orphan medicines reach patients across Europe Avanzanite Bioscience B.V. (“Avanzanite”), a fast-growing commercial-stage specialty pharmaceutical company dedicated to bringing rare disease medicines to patients across Europe, announced today an exclusive agreement with Agios Pharmaceuticals Inc. (Nasdaq: AGIO), a Boston-based biotech company focused on the development and commercialization of rare disease medicines. Under the agreement, Avanzanite will commercialize and distribute PYRUKYND® (mitapivat) across the European Economic Area, the UK and Switzerland. This press release features multimedia. View the ful

Tier-1 MVNO Selects Tecnotree’s AI-Native BSS for Multi-Country Transformation Across UK & Europe9.6.2025 14:36:00 CEST | Press release

Tecnotree, the global pioneer in AI-native Digital BSS and fintech platforms, has announced a major multi-year, multi-country agreement with a Tier-1 Mobile Virtual Network Operator (MVNO) to transform its operations across the United Kingdom and Europe. The deal, valued at USD 19.58 million over five years, positions Tecnotree at the forefront of next-generation MVNO enablement in mature, highly competitive telecom markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609328949/en/ This engagement will see the full-stack replacement of the MVNO’s legacy systems with Tecnotree’s composable, cloud-native BSS—an AI-first, TM Forum ODA-aligned platform engineered for speed, scale, and interoperability. Designed to unlock real-time personalization, agile service orchestration, and embedded financial ecosystems, this transformation lays the foundation for the MVNO to compete with intelligence and grow with intent. The deploy

Innospera Pharma Appoints Dr. Glenn Crater as Chief Medical Officer to Support Advancement of ING-006 Toward the Clinic9.6.2025 14:00:00 CEST | Press release

Innospera Pharma Inc. (“Innospera”), a private, near-clinical-stage biotechnology company advancing differentiated small molecule modulators of GPR84 and GPR40 to treat inflammatory and metabolic diseases, today announced the appointment of Dr. Glenn Crater, MD, FCCP as Chief Medical Officer (CMO). Glenn will start immediately as a fractional CMO, with the commitment to joining full time as the Company’s lead compound reaches the clinic. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609975546/en/ Glenn Crater, MD, FCCP, appointed Chief Medical Officer of Innospera Pharma Dr. Crater brings to Innospera over 25 years of clinical, regulatory, and leadership experience in pulmonary medicine and drug development. A board-certified pulmonologist, Dr. Crater has played pivotal roles in advancing respiratory drug candidates, with particular expertise in Idiopathic Pulmonary Fibrosis (IPF) — the initial target indication for Inno

Butterfly Network’s RoHS Lead Exemption Revocation Request Progresses to Stakeholder and Consultant Assessment9.6.2025 14:00:00 CEST | Press release

Oeko-Institut appointed for third-party evaluation; stakeholder consultation will run June 6, 2025 - August 1, 2025 Butterfly Network, Inc. (“Butterfly”, “the Company”) (NYSE: BFLY), a digital health company transforming care with handheld, whole-body ultrasound, today announced that the European Commission has officially initiated the review and stakeholder consultation period for the Company’s request to revoke Annex IV n. 14 of the European Commission’s Restriction of Hazardous Substances (RoHS) Directive – a temporary exemption historically granted for lead in single crystal piezoelectric materials for ultrasonic transducers. Following Butterfly’s revocation submission in October 2024, the Commission has now appointed the Oeko-Institut as consultant to lead the technical assessment of the request, including a third-party evaluation. The stakeholder consultation questionnaire is open and will run from June 6, 2025 to August 1, 2025, allowing interested parties to submit feedback. A

Opengear Unveils Integrated Support Platform to Empower Always-On Infrastructure9.6.2025 14:00:00 CEST | Press release

New integrated support model offers embedded protection, SLA-backed tiers, and simplified ownership — previewing at Cisco Live 2025 Opengear, a Digi International company (NASDAQ: DGII, www.digi.com) and provider of secure and Smart Out of Band™ management solutions, today announced a major transformation in how organizations buy, deploy, and maintain their network infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609348748/en/ Opengear Unveils Integrated Support Platform to Empower Always-On Infrastructure. Beginning this month, every new Opengear appliance will ship with five years of built-in hardware coverage and inclusive SLA-backed support. This shift turns support into a strategic asset, enabling IT leaders to plan more confidently, reduce risk, and simplify the path to network resilience. “This marks a meaningful evolution in the way we support our customers,” said Patrick Quirk, President and General

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye